Analysis of Patients’ Characteristics and Treatment Profile of People Who Use Drugs (PWUDs) with and without a Co-Diagnosis of Viral Hepatitis C: A Real-World Retrospective Italian Analysis

References

• World Health Organization. Global health sector strategy on viral hepatitis 2016–21. Available from: https://apps.who.int/iris/handle/10665/246177. Accessed February 16, 2023.
   Google Scholar
• Papatheodoridis GV, Hatzakis A, Cholongitas E, et al. Hepatitis C: the beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat. 2018;25(Suppl 1):6–17. doi:10.1111/jvh.12875
   Google Scholar
• Doerrbecker J, Behrendt P, Mateu-Gelabert P, et al. Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. J Infect Dis. 2013;207(2):281–287. doi:10.1093/infdis/jis677
   PubMed Web of Science ®Google Scholar
• Mangia A, Rina MF, Canosa A, et al. Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient-centered program from Italy. United Eur Gastroenterol J. 2021;9(10):1109–1118. doi:10.1002/ueg2.12156
   PubMed Web of Science ®Google Scholar
• Beaulieu T, Hayashi K, Milloy MJ, et al. HIV serostatus and having access to a physician for regular hepatitis C virus care among people who inject drugs. J Acquir Immune Defic Syndr. 2018;78(1):93–98. doi:10.1097/QAI.0000000000001651
   PubMed Web of Science ®Google Scholar
• Martin NK, Vickerman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS. 2015;10(5):374–380. doi:10.1097/COH.0000000000000179
   PubMed Web of Science ®Google Scholar
• Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis. 1995;15(1):82–91. doi:10.1055/s-2007-1007265
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–1374. doi:10.1002/hep.22759
   PubMed Web of Science ®Google Scholar
• Alimohammadi A, Holeksa J, Thiam A, Truong D, Conway B. Real-world efficacy of direct-acting antiviral therapy for HCV infection affecting people who inject drugs delivered in a multidisciplinary setting. Open Forum Infect Dis. 2018;5(6):ofy120. doi:10.1093/ofid/ofy120
   PubMed Web of Science ®Google Scholar
• Grebely J, Hajarizadeh B, Dore GJ. Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol. 2017;14(11):641–651. doi:10.1038/nrgastro.2017.106
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012;55(5):1620–1628. doi:10.1002/hep.25653
   PubMed Web of Science ®Google Scholar
• Talavera Pons S, Boyer A, Lamblin G, et al. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol. 2017;83(2):269–293. doi:10.1111/bcp.13095
   PubMed Web of Science ®Google Scholar
• Curry MP, Flamm SL, Milligan S, et al. Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study. J Manag Care Spec Pharm. 2021;27(9):1239–1248. doi:10.18553/jmcp.2021.20550
   PubMed Web of Science ®Google Scholar
• Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology. 1997;26(4):1006–1011. doi:10.1002/hep.510260431
   PubMed Web of Science ®Google Scholar
• Kondili LA, Robbins S, Blach S, et al. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? Liver Int. 2018;38(12):2190–2198. doi:10.1111/liv.13901
   PubMed Web of Science ®Google Scholar
• Mangia A, Scaglione F, Toniutto P, et al. Drug-drug interactions in Italian patients with chronic hepatitis C treated with pangenotypic direct acting agents: insights from a real-world study. Int J Environ Res Public Health. 2021;18(13):7144. doi:10.3390/ijerph18137144
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Stigliano G, Miuli A, Lalli A, et al. An Italian survey of opioids misuse: epidemiological and psychopathological aspects. Emerg Trends Drugs Addict Health. 2021;1:100029. doi:10.1016/j.etdah.2021.100029
   Google Scholar
• Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–e1207. doi:10.1016/S2214-109X(17)30375-3
   PubMed Web of Science ®Google Scholar
• Relazione annuale al Parlamento sul fenomeno delle tossicodipendenze in Italia-2021 (dati 2020). Available from: https://antidroga.interno.gov.it/d-p-A-relazione-annuale-al-parlamento-sul-fenomeno-delle-tossicodipendenze-in-italia-anno-2021-dati-2020/. Accessed February 16, 2023.
   Google Scholar
• Teti E. Hepatitis C management and treatment among people who inject drugs in Italy: an exploratory pilot survey. Mission. 2020. doi:10.3280/mis54-2020oa9744
   Google Scholar
• Alkhouri N, Lawitz E, Poordad F. Novel treatments for chronic hepatitis C: closing the remaining gaps. Curr Opin Pharmacol. 2017;37:107–111. doi:10.1016/j.coph.2017.10.001
   PubMed Web of Science ®Google Scholar
• Hepatitis B and C testing in the EU/EEA: progress in reaching the elimination targets. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Hepatitis-B-and%20C-Testing-in-The-EU-EEA-and-UK.pdf. Accessed February 16, 2023.
   Google Scholar
• Registri AIFA per il monitoraggio dei farmaci anti-HCV. Available from: https://www.aifa.gov.it/aggiornamento-epatite-c. Accessed February 16, 2023.
   Google Scholar
• Viganò M, Perno CF, Craxì A; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party. Treatment of Hepatitis C virus infection in Italy: a consensus report from an expert panel. Dig Liver Dis. 2017;49(7):731–741. doi:10.1016/j.dld.2017.03.027
   PubMedGoogle Scholar
• Fagiuoli S, Toniutto P, Coppola N, et al. Italian real-world analysis of the impact of polypharmacy and aging on the risk of multiple Drug-Drug Interactions (DDIs) in HCV patients treated with Pangenotypic Direct-Acting Antivirals (pDAA). Ther Clin Risk Manag. 2023;19:57–65. doi:10.2147/TCRM.S394467
   PubMed Web of Science ®Google Scholar
• Marcos-Fosch C, Cabezas J, Crespo J, Buti M. Anti-epileptc drugs and hepatitis C therapy: real-world experience. J Hepatol. 2021;75(4):984–985. doi:10.1016/j.jhep.2021.05.040
   PubMed Web of Science ®Google Scholar
• Lim J, Pavalagantharajah S, Verschoor CP, et al. Infectious diseases, comorbidities and outcomes in hospitalized people who inject drugs (PWID) infections in persons who inject drugs. PLoS One. 2022;17(4):e0266663. doi:10.1371/journal.pone.0266663
   PubMed Web of Science ®Google Scholar
• Wurcel AG, Burke DJ, Wang JJ, et al. The burden of untreated HCV infection in hospitalized inmates: a hospital utilization and cost analysis. J Urban Health. 2018;95(4):467–473. doi:10.1007/s11524-018-0277-z
   PubMed Web of Science ®Google Scholar
• Chevaliez S, Pawlotsky JM. Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. Int J Med Sci. 2006;3(2):35–40. doi:10.7150/ijms.3.35
   PubMedGoogle Scholar